Total Payments
$3.0M
2024 Payments
$309,126
Companies
63
Transactions
2,443
Medicare Patients
867
Medicare Billing
$152,611
Payment Breakdown by Category
Other$1.5M (49.9%)
Consulting$940,114 (31.4%)
Travel$417,973 (14.0%)
Research$87,401 (2.9%)
Food & Beverage$54,280 (1.8%)
Education$275.70 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 396 | 48.3% |
| Consulting Fee | $940,114 | 305 | 31.4% |
| Travel and Lodging | $417,973 | 859 | 14.0% |
| Unspecified | $87,401 | 62 | 2.9% |
| Food and Beverage | $54,280 | 796 | 1.8% |
| Honoraria | $46,343 | 17 | 1.5% |
| Grant | $1,078 | 2 | 0.0% |
| Education | $275.70 | 6 | 0.0% |
Payments by Type
General
$2.9M
2,381 transactions
Research
$87,401
62 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $596,703 | 314 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $448,327 | 350 | $0 (2024) |
| TESARO, Inc. | $364,550 | 391 | $0 (2019) |
| Merck Sharp & Dohme LLC | $324,929 | 304 | $0 (2024) |
| Clovis Oncology, Inc. | $178,531 | 207 | $0 (2022) |
| Genentech USA, Inc. | $153,681 | 123 | $0 (2019) |
| Genmab U.S., Inc. | $138,705 | 104 | $0 (2024) |
| Seagen Inc. | $110,842 | 87 | $0 (2023) |
| Eisai Inc. | $83,975 | 73 | $0 (2024) |
| Myriad Genetic Laboratories, Inc. | $82,216 | 71 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $309,126 | 246 | Genmab U.S., Inc. ($78,285) |
| 2023 | $329,365 | 214 | GlaxoSmithKline, LLC. ($123,326) |
| 2022 | $402,929 | 266 | GlaxoSmithKline, LLC. ($145,368) |
| 2021 | $410,109 | 234 | GlaxoSmithKline, LLC. ($155,088) |
| 2020 | $299,252 | 203 | GlaxoSmithKline, LLC. ($116,475) |
| 2019 | $561,322 | 542 | TESARO, Inc. ($144,438) |
| 2018 | $376,910 | 424 | TESARO, Inc. ($137,555) |
| 2017 | $303,179 | 314 | TESARO, Inc. ($82,558) |
All Payment Transactions
2,443 individual payment records from CMS Open Payments — Page 1 of 98
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | PFIZER INC. | TIVDAK (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,175.00 | General |
| Category: Oncology | ||||||
| 12/14/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $24.72 | General |
| 12/13/2024 | Genmab U.S., Inc. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 12/13/2024 | Genmab U.S., Inc. | — | Food and Beverage | Cash or cash equivalent | $94.91 | General |
| 12/13/2024 | Genmab U.S., Inc. | — | Food and Beverage | Cash or cash equivalent | $44.29 | General |
| 12/12/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $626.71 | General |
| 12/12/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $59.91 | General |
| 12/12/2024 | Genmab U.S., Inc. | — | Food and Beverage | Cash or cash equivalent | $26.13 | General |
| 12/11/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $8,971.29 | General |
| 12/11/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $2,432.66 | General |
| 12/11/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $255.50 | General |
| 12/10/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,125.00 | General |
| Category: Oncology | ||||||
| 11/28/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $3,720.00 | General |
| 11/28/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $620.00 | General |
| 11/22/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Travel and Lodging | In-kind items and services | $2,144.43 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Travel and Lodging | Cash or cash equivalent | $296.42 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | Cash or cash equivalent | $38.42 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $7,930.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,490.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/17/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $110.81 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH OLAPARIB IN PATIENTS WITH NO GERMLINE BRCA MUTATION DETECTED, PLATINUM-RESISTANT OR REFRACTORY, HIGH GRADE SEROUS OVARIAN CANCER | Novartis Pharmaceuticals Corporation | $64,243 | 1 |
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $10,556 | 33 |
| An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma | Regeneron Pharmaceuticals, Inc. | $9,197 | 5 |
| A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1-POSITIVE CERVICAL CANCER | F. Hoffmann-La Roche AG | $1,340 | 1 |
| Libtayo Clinical Publication Program | Regeneron Pharmaceuticals, Inc. | $561.52 | 3 |
| CBYL719K12301 - EPIK-O | Novartis Pharma AG | $345.84 | 1 |
| Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer | Seattle Genetics, Inc. | $345.49 | 9 |
| A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Metastatic Cervical Cancer | Seattle Genetics, Inc. | $339.54 | 7 |
| TUKYSA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| CBYL719K12301 | Novartis Pharmaceuticals Corporation | $142.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 37 | 53 | $12,816 | $2,830 |
| 2022 | 4 | 67 | 81 | $27,555 | $5,697 |
| 2021 | 17 | 421 | 2,747 | $314,230 | $75,163 |
| 2020 | 18 | 342 | 8,245 | $306,438 | $68,920 |
Total Patients
867
Total Services
11,126
Medicare Billing
$152,611
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 30 | $8,400 | $1,824 | 21.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 23 | $4,416 | $1,006 | 22.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 36 | $9,218 | $2,075 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 18 | $6,907 | $1,644 | 23.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 12 | 13 | $8,658 | $1,303 | 15.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 14 | $2,772 | $675.79 | 24.4% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 24 | 160 | $106,560 | $18,075 | 17.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 33 | 110 | $17,600 | $17,600 | 100.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 85 | 152 | $32,984 | $13,928 | 42.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 44 | 71 | $20,732 | $9,524 | 45.9% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2021 | 16 | 63 | $20,412 | $3,457 | 16.9% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 21 | 263 | $26,826 | $3,419 | 12.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $6,704 | $2,632 | 39.3% |
| 86304 | Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | Office | 2021 | 35 | 79 | $9,480 | $1,644 | 17.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 29 | 142 | $4,828 | $1,103 | 22.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 26 | 99 | $5,940 | $1,045 | 17.6% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 12 | 41 | $6,068 | $1,010 | 16.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2021 | 12 | 410 | $50,020 | $726.64 | 1.5% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis, concurrent with another infusion | Office | 2021 | 11 | 31 | $2,728 | $508.40 | 18.6% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2021 | 13 | 14 | $1,512 | $308.42 | 20.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 19 | 990 | $990.00 | $114.55 | 11.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2021 | 13 | 54 | $378.00 | $33.94 | 9.0% |
| J3490 | Unclassified drugs | Office | 2021 | 12 | 52 | $468.00 | $33.34 | 7.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 20 | 102 | $16,320 | $16,176 | 99.1% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 21 | 96 | $63,936 | $10,437 | 16.3% |
About Dr. Bradley Monk, MD
Dr. Bradley Monk, MD is a Gynecologic Oncology healthcare provider based in West Palm Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487734646.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bradley Monk, MD has received a total of $3.0M in payments from pharmaceutical and medical device companies, with $309,126 received in 2024. These payments were reported across 2,443 transactions from 63 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Monk has provided services to 867 Medicare beneficiaries, totaling 11,126 services with total Medicare billing of $152,611. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Location West Palm Beach, FL
- Active Since 10/16/2006
- Last Updated 01/30/2026
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1487734646
Products in Payments
- ZEJULA (Drug) $634,895
- LYNPARZA (Drug) $414,493
- Rubraca (Drug) $174,486
- Avastin (Biological) $156,206
- TIVDAK (Biological) $115,638
- KEYTRUDA (Biological) $113,376
- JEMPERLI (Biological) $86,325
- Tivdak (Drug) $84,462
- Lenvima (Drug) $80,857
- GARDASIL (Biological) $55,821
- TIVDAK (Drug) $37,576
- MYCHOICE CDX (Device) $33,061
- myChoice CDx (Device) $32,108
- LIBTAYO (Biological) $29,360
- ELAHERE (Drug) $28,277
- BAVENCIO (Drug) $26,515
- IMFINZI (Biological) $19,694
- YONDELIS (Drug) $17,249
- DARZALEX (Biological) $15,585
- PreciseTumor (Device) $14,566
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.